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Cost-effective Screening and Treatment of Hepatitis C
Abstract
In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily
cured by a short course of medication. Medical breakthroughs have now created the possibility of
eliminating the transmission of HCV, but also bring a new challenge for the health system—how to identify
individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief
reviews recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the
case for universal, one-time HCV screening for all US adults.

Keywords
Hepatitis C, HCV, HCV screening, cost-effectiveness

License
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 License.

This brief is available at ScholarlyCommons: https://repository.upenn.edu/ldi_issuebriefs/125

Center for Health Economics of Treatment Interventions for
Substance Use Disorder, HCV, and HIV

September 2018 - Issue Brief

Janet Weiner, PhD, MPH

Co-Director for Health Policy, Leonard
Davis Institute of Health Economics
University of Pennsylvania

Benjamin Linas, MD, MPH

Associate Professor of Medicine
Boston University School of Medicine

Cost-effective screening and treatment of
Hepatitis C

I

n just five years, hepatitis C has changed from a difficult-to-treat chronic
condition to one that is readily cured by a short course of medication. Medical
breakthroughs have now created the possibility of eliminating the transmission of
HCV, but also bring a new challenge for the health system—how to identify
individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving
treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of
screening and treatment strategies, and makes the case for universal, one-time
HCV screening for all US adults.
Background
More than 3.5 million people in the US are chronically infected with HCV, and about 19,000
die each year from HCV-related diseases. Hepatitis C is a leading cause of liver cancer and
the leading cause of liver transplants; baby boomers (people born during 1945-1965)
account for three-quarters of all cases and hepatitis C-related deaths. The incidence of HCV
infection is rising in younger people, primarily because of injection drug use.

This Issue Brief reviews
recent evidence on the
cost-effectiveness of

HCV

screening and treatment

strategies, and makes the
case for universal,

one-time screening for
all

US adults.

A high proportion (from 45% to 85%, according the CDC) are unaware that they have the
disease, and may infect others. In 1998, the CDC recommended HCV testing only for people
at high risk—such as a history of injection drug use or exposure to blood products before
effective screening—a strategy that left most people unaware of their status. Because of a
disproportionately high prevalence of hepatitis C among baby boomers, the CDC
augmented their recommendations in 2012 to include one-time testing of all people in that
birth cohort. In 2013 the US Preventive Services Task Force (USPSTF) gave this
recommendation a “B” grade, which meant that the screening would be covered by
insurance with no cost-sharing under the Affordable Care Act. A few months later, the first
efficacious direct-acting anti-virals hit the market, offering a nearly 90% cure rate and the
potential to eliminate transmission of HCV. That potential, however, was limited by the
initial price tag ($84,000 per course of treatment) and the budget impact on public payers,
such as Medicaid and Departments of Corrections, who cover a disproportionate number
of people with HCV. In response, these payers have limited treatments to patients with
advanced disease or used other restrictions.
In an era of effective treatments, identifying people with hepatitis C takes on even greater
urgency as the beginning step in a “cascade of care” leading to cure, and potential
elimination of HCV transmission. But the combination of a prevalent disease with an
expensive cure, and the burden of treatment on public budgets, creates a significant
economic barrier to HCV care.
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New screening guidelines have an impact

Screening rates jump after
CDC recommends HCV
screening of all baby
boomers

In a study of the effects of the new CDC testing guidelines, Barocas, Wang, White, et al.
(2017) found an “immediate and sustained impact of hepatitis C testing guidelines on
clinical practice.” They analyzed hepatitis C screening rates in 2.8 million commercially
insured adults before and after the recommendations, using a cohort born after 1965 (but
at least 18 years old) as a comparison group. As shown below, they found a 49% increase in
screening rates among the birth cohort after the release of the recommendations, but no
increase among the comparison cohort.
Figure 1
Trends in quarterly hepatitis C screening rates in the United States per 100 person-years in 2010-14, by age cohort

Source: Joshua A. Barocas, Jianing Wang, Laura F. White, Abriana Tasillo, Joshua A. Salomon, Kenneth A.
Freedberg, and Benjamin P. Linas. Hepatitis C Testing Increased Among Baby Boomers Following The 2012
Change To CDC Testing Recommendations. Health Affairs, 2017 36:12, 2142-2150

Rodriguez, Rubenstein, Linas, et al. (2018) confirmed the effects of the CDC and USPSTF
screening recommendations in an observational study of 665,000 adults visiting
Kaiser Permanente clinics between 2003 and 2014. They documented a steady increase in
screening over time, with a noticeable jump in screening after the USPSTF
recommendations. As shown below, HCV screening jumped 29% from 2013-2014,
compared to 4% from 2012-2013.
Figure 2
HCV screening rate over time, Kaiser Permanente, 2003-2014

Source: Rodriguez CV, Rubenstein KB, Linas B, Hu H, Horberg M. Increasing hepatitis C screening in a
large integrated health system: science and policy in concert. American Journal of Managed Care, 2018 May
1;24(5):e134-e140.
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Adjusting for other factors, the authors found that screening in the birth cohort more than
doubled, which represented a 20% greater increase than screening in other age groups.
The authors point out that insurance coverage for screening and the availability of effective
treatment after the USPSTF recommendation may have led to a greater increase in
screening than screening guidelines alone.

Compared to treating more
advanced disease only,
treating early disease is

likely cost-effective, and
may even be cost-saving.

HCV treatment provides good value
Despite its cost, HCV treatment provides good value for the money, as expressed in terms
of cost-effectiveness. In a recent review, Linas and Nolen (2018) note that most studies
in the past five years find that HCV treatment falls within the generally accepted value of
$100,000 per quality-adjusted life year (QALY). They note that these studies do not reflect
price decreases that have occurred in the past 1-2 years—but the substantial cost burden
remains. A critical question is not whether to treat patients with HCV, but when, because of
the significant lag time between infection and disease. Facing costs that could overwhelm
fixed budgets, many payers have restricted treatments to those with advanced disease
(for example, liver cirrhosis) or those who are alcohol- or drug-free.
In one study, Linas, Morgan, Pho, et al. (2017) modeled the cost-effectiveness and
budgetary impact of different treatment strategies, from a payer’s point of view. They
found that the five-year budgetary impact of treating HCV was high ($1-$2.3 billion per
10,000 HCV-infected patients, depending on the treatment regimen). They confirmed that
the treatment strategies are cost-effective; compared to treating more advanced disease
only, treating early disease is likely cost-effective, and may even be cost-saving, because it
prevents many years of decreased quality of life and increased health care costs associated
with HCV infection. They conclude that payers seeking to control costs would do better by
price negotiations in a newly competitive drug market rather than by treatment restrictions.
Treating all HCV-infected people with the least costly direct-acting antiviral would be the
cost-control strategy that produces the best outcomes.
There is some evidence that public payers are relaxing their eligibility restrictions (such as
disease severity and substance use abstinence) for hepatitis C treatment. Kapadia, Jeng,
Schackman, and Bao (2017) looked at Medicaid drug utilization data from 2014 to 2016,
and found that states that loosened their restrictions had a more rapid increase in
prescriptions of direct-acting antivirals than states maintaining their restrictions. The 31
states that implemented Medicaid expansion under the Affordable Care Act saw much
more of an increase in utilization than states that did not.

What’s the optimal HCV screening strategy?
Using a simulation model, Barocas, Tasillo, Eftekhari Yazdi, et al. (2018) compared the
clinical costs, outcomes, and cost-effectiveness of four HCV testing strategies: the
existing one (one-time testing for all persons born between 1945 and 1965); one-time
testing for adults aged 40 or higher, 30 or higher, or 18 or higher. All strategies included
targeted testing of people at higher risk, such as those who inject drugs. As shown
below, expanded age-based strategies increased identification and lifetime cure rates.
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Figure 3
HCV continuum of care over a lifetime, by strategy

One-time screening of
all US adults would be
cost-effective, providing
the greatest qualityadjusted life expectancy
and lowest cost per

QALY gained.

Source: Joshua A. Barocas, Abriana Tasillo, Golnaz Eftekhari Yazdi, Jianing Wang, Claudia Vellozzi, Susan
Hariri, Cheryl Isenhour, Liisa Randall, John W. Ward, Jonathan Mermin, Joshua A. Salomon, Benjamin P.
Linas. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based
Hepatitis C Testing in the United States. Clinical Infectious Diseases, Volume 67, Issue 4, 1 August 2018, Pages
549–556, https://doi.org/10.1093/cid/ciy098

The authors estimate that the existing strategy would identify 71% of all HCV-infected
people, and 44% of them would be cured over a lifetime. Compared to existing screening,
a strategy of age 18 or older would result in 256,000 additional people identified, 28,000
additional cures, and 4,400 fewer cases of hepatocellular liver cancer over the lifetime
of this age group. For people born outside the baby boomer cohort, case detection rates
would increase from 74% to 85%, and cure rates would increase from 49% to 61%. Overall,
this would represent a 21% reduction in liver-attributable mortality, and an increase in life
expectancy from 67.2 to 68.2 years among the affected population.
All strategies decreased the costs related to managing chronic HCV and advanced liver
disease. The cost of HCV testing in the existing strategy amounted to $2,500 per case
diagnosed; in the 18 and over strategy, the cost of testing increased to $4,400 per case
diagnosed. The 18 and over strategy was cost-effective, providing the greatest
quality-adjusted life expectancy and the lowest cost/QALY gained ($28,000 per QALY).
Figure 3 above also illustrates the importance of linking identified patients to care in an
overall strategy that produces high cure rates. Schackman, Gutkind, Morgan, et al. (2018)
modeled the cost-effectiveness of screening and treatment linkages in a high-risk
population of patients in a methadone maintenance treatment (MMT) program, using data
from a randomized trial. The study estimated costs and outcomes of on-site HCV screening
and education or HCV screening, education, and active care coordination, compared to
no intervention. The model took into account the probability of reinfection if patients
engaged in injection drug use risk behavior.
As shown in Figure 4, on-site screening and education resulted in a projected 35% linking
to care within six months and 31% achieving cure (sustained virologic response). Adding an
active coordination component resulted in 60% linking and 54% achieving cure. The active
care coordination intervention had a cost-effectiveness ratio of $24,600/QALY gained,
compared to no intervention, and $76,500/QALY gained, compared to screening and
education alone. Thus, the authors conclude that HCV care coordination interventions that
include screening, education and active linkage to care in MMT settings are likely
cost-effective at a conventional $100,000/QALY threshold.
LDI/CHERISH Issue Brief - Cost-effective screening and treatment of Hepatitis C

4

Figure 4
Projected short-term and lifetime continuum of care results, by intervention group

In economic models and
real-world practice,
identifying patients with

Hepatitis C and linking

them to early treatment
provides good value for

our health care dollar.
Source: Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman
DC, Masson CL, Linas BP. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in
US methadone maintenance treatment programs. Drug and Alcohol Dependence, 2018 Apr 1;185:411-420. doi:
10.1016/j.drugalcdep.2017.11.031.

In an economic analysis of a real-world HCV care coordination program in two New York
City clinics, Behrends, Eggman, Gutkind, et al. (2018) found that the cost of a 5.6-month
care coordination intervention was less than $800 including overhead. The authors
proposed a three-part payment model tied to each phase of the program: enrollment to
treatment initiation, treatment initiation to treatment completion, and a bonus payment
for laboratory evidence of sustained viral response.

Policy Implications
Hepatitis C treatment lies at the crossroads of science, economics, and policy. As Linas and
Nolen (2018) note, with effective treatments in hand, the challenge has shifted from the
biology of curing a virus to the public health problem of identifying and treating millions of
HCV-infected people.
The economics of the problem highlight the difference between cost-effectiveness, from
the health system or societal perspective, and the budget impact for payers, especially
public ones. There is considerable evidence that a variety of strategies for screening and
treating HCV provide good value for their cost, at conventionally accepted standards for
value. This is especially impressive given that the costs used in these analyses were higher
than HCV treatments today; as competing medications enter the market, the cost of a cure
has dropped from $84,000 to $26,400 (before discounts) for some regimens.
Screening recommendations from the CDC and USPSTF have increased HCV testing in
clinical practice, especially among the baby boomer cohort that they target. However,
evidence suggests that one-time testing of all people 18 and over would be more
cost-effective, identify more cases, and yield greater cures. Given the impact of the
previous change in CDC and USPSTF recommendations, changing them again would likely
result in more screening and more treatment.
But what is cost-effective may not be affordable within specific budgets. Further, future
savings may not accrue to the same payers that would have to absorb the considerable
present costs of screening and treatment. This is particularly true for payers with
disproportionately high prevalence of HCV infection in their populations, such as
Medicaid and correctional institutions.
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At this time, the question
is not should we test and

treat, but how will we pay
for it.

Given this context, some policymakers are exploring new ways to pay for HCV treatment.
For example, the Secretary of Health in Louisiana is exploring a subscription-based
payment model in which the state would pay a drug manufacturer a fixed purchase price
for the length of a multi-year contract. The price would provide unlimited treatment access
for people covered by Medicaid or in Louisiana’s correctional system. If structured
properly, the model would allow the state to spread the costs of treatment across budget
years, while expanding the manufacturer’s reach into populations that are not now being
treated.
The National Academies of Sciences, Engineering, and Medicine proposed a novel strategy
that involves drug manufacturers competing to license their patent to the federal
government for use in low-income and vulnerable populations. In that case, generic
manufacturers could supply Medicaid and correctional institutions with HCV treatments
at much lower cost, while protecting the market share of drug manufacturers in the private
market.

Conclusion
In economic models and in real-world practice, identifying patients with hepatitis C
infection and linking them to early treatment provides good value for our health care
dollar. We conclude that:
1. Routine screening for HCV, without effort to identify risk factors, is cost-effective
and even cost-saving in some venues.
2. HCV treatment is cost-effective, even with high-cost medications and even with
high reinfection rates.
At this time, the question is not “should” we test and treat, but “how will we pay for it?”
This is not a trivial question, but it is one that is best answered through financial
instruments, not treatment restrictions. Rather than seek strategies that minimize cost by
limiting treatment courses, health care systems and policymakers should negotiate
aggressively holding the “chip” of large volume to drive down cost and should design
financing schemes that help them to disperse cost over time.
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